Skip to main content
Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8+ T cells without host preconditioning

Fig. 3

Administration of LPS enhances antitumor immunity in irradiated but not lymphoreplete mice. a LPS does not augment antitumor responses in non-irradiated mice. Mice bearing subcutaneous B16F10 tumors were established for 8 days. Mice received an ACT treatment comprised of the adoptive transfer of 5e5 cultured pmel-1 T cells, fowlpox hgp100 vaccination and hIL-2 or were left untreated. The next day, mice received ultra-pure LPS ranging from 0.5 to 5 μg or left untreated. Data shown (mean ± SEM, 10 mice per group) are representative of 2 independent experiments. PFI vs. PFI + 0.5, 1 or 5 LPS, NS, ANOVA. b LPS augments the antitumor activity of pmel-1 CD8+ T cells in irradiated mice. Mice bearing subcutaneous B16F10 tumors established for 8 days received 5Gy TBI. One day after TBI, mice received an ACT treatment comprised of the adoptive transfer of 5e5 cultured pmel-1 T cells, fowlpox hgp100 vaccination and hIL-2 or were left untreated. The next day, mice received LPS ranging from 0.5 to 5 μg or left untreated. Data shown (mean ± SEM, 5–10 mice per group) are representative of 2 independent experiments. 5 Gy PFI (white circle) vs. 5Gy PFI + 0.5 LPS (white square), NS. ANOVA. 5Gy PFI + 0.5 LPS (white square) vs. 5 Gy PFI + 1 or 5 LPS (grey or black square), ***P < .001, ANOVA

Back to article page